Sitting for over 10 hours or more a day is significantly linked to future heart failure and cardiovascular death risk, a new ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

Twin sisters living with heart failure are calling for an end to what they say is a postcode lottery when it comes to ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

We know that exercise is good for our hearts and overall health. But is that true for people living with heart failure? And ...

The second arm of the trial was the placebo arm (n = 367). The final primary endpoints of SUMMIT were a combination of ...

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

The existing oral and intravenous forms of bumetanide are commonly prescribed for people with heart failure because they ease tissue swelling, a common cause of symptoms for people with heart failure.